

INDEPENDENT HEALTH'S PREVENTIVE LISTING AS OF SEPTEMBER 1, 2023

All codes appearing in this document may not be eligible for reimbursement to all physicians or provider due to individual procedure privileging requirements, reimbursement or medical management policy established by Independent Health or as determined by the member's individual contract or summary plan description (SPD) benefit language. We cover the following services for the purpose of prompting good health and early detection of disease. Preventive services are not subject to Cost-Sharing (Copayments, Deductible or Coinsurance) when performed by a Participating Provider and in accordance with the comprehensive guidelines supported by the Health Resources and Services Administration ("HRSA"), or if the items or services have an "A" or "B" rating from United States Preventive Services Task Force ("USPSTF") or if the immunizations are recommended by Advisory Committee on Immunization Practices ("ACIP"). This applies to Commercial, Essential Plan and Self-Funded where applicable. Some Self-funded plans are grandfathered and may not cover a preventive service or apply cost share. All codes are subject to industry standard NCCI bundling.

Procedure Category	Code	Code Description Code Description	Covered Limitations
Abdominal Aortic Aneurysm Screening	76706	Ultrasound B-scan and/or real time with image documentation; for abdominal aortic aneurysm (AAA) screening	Specific for men ages 65 to 75 years who have ever smoked.
Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality; Preventive Medication; pregnant persons at high risk for preeclampsia	Will be billed with NDC to pharmacy (script required)		Commercial- paid as a medical benefit Self-funded - paid as a prescription benefit
Assessment for risks for cardiac arrest or death in ages 11-21 years	Part of office visit		New HRSA recommendation effective 1.1.23.
Assessment for Hepatitis virus infection in newborn to 21-year-old	Part of office visit		New HRSA recommendation effective 1.1.23.
Asymptomatic Bacteriuria Screening in Pregnant Women	81007	Urinalysis; bacteriuria screen, except by culture or dipstick	Primary Diagnosis: Pregnancy
	87081	Culture, presumptive, pathogenic organisms, screening	Primary Diagnosis: Pregnancy
	87084	Culture, presumptive, pathogenic organisms, screening with colony estimation with density chart	Primary Diagnosis: Pregnancy
	87086	Culture, bacterial, quantitative colony count, urine	Primary Diagnosis: Pregnancy

	87088	Culture, bacterial, quantitative colony count, urine with isolation and presumptive identification of each isolate, urine	Primary Diagnosis: Pregnancy
Bone Density (Osteoporosis Screening)	76977	Ultrasound bone density measurement and interpretation, peripheral site(s), any method	Specific to women 65 years and older and for post-menopausal women under 65 who are at increased risk
	77078	Computed tomography, bone mineral density study, 1 or more sites; axial skeleton (e.g., hips, pelvis, spine)	Specific to women 65 years and older and for post-menopausal women under 65 who are at increased risk
	77080	Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (e.g., hips, pelvis, spine)	Specific to women 65 years and older and for post-menopausal women under 65 who are at increased risk
	77081	Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; appendicular skeleton (peripheral) (e.g., radius, wrist, heel)	Specific to women 65 years and older and for post-menopausal women under 65 who are at increased risk
	77085	Dual-energy x-ray absorptiometry (DXA) bone density study, 1 or more sites; axial skeleton including vertebral fracture assessment	Specific to women 65 years and older and for post-menopausal women under 65 who are at increased risk
	78350	Bone mineral density (bone mineral content) study; 1 or more sites: single photon absorptiometry	Specific to women 65 years and older and for post-menopausal women under 65 who are at increased risk
	78351	Bone mineral density (bone mineral content) study; 1 or more sites: dual photon absorptiometry	Specific to women 65 years and older and for post-menopausal women under 65 who are at increased risk
	G0130	Single energy x-ray absorptiometry (SEXA) bone density study, one or more sites; appendicular skeleton (peripheral) (e.g., radius, wrist, heel).	Specific to women 65 years and older and for post-menopausal women under 65 who are at increased risk
<p>BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic testing: women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or an ancestry associated with brca1/2 gene mutation* BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic testing: women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or an ancestry associated with brca1/2 gene mutation*</p> <p>*Please note: BRCA mutation screening requires provider preauthorization to review for medical necessity based on product. Reference the following policy for additional information: Breast Cancer Susceptibility 1 and 2 (BRCA 1/2) Sequence Testing for Susceptibility to Hereditary Breast</p>			
	81162	BRCA1, BRCA2 (breast Cancer 1 and 2) (egg. Hereditary breast and ovarian cancer) gene analysis, full sequence analysis and full duplication/deletion	

	81163	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (e.g., hereditary breast and ovarian cancer) gene analysis; full sequence analysis	
	81164	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (e.g., hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis	
	81165	BRCA1 (BRCA1, DNA repair associated) (e.g., hereditary breast and ovarian cancer) gene analysis full sequence analysis	
	81166	BRCA1 (BRCA1, DNA repair associated) (e.g., hereditary breast and ovarian cancer) gene analysis full duplication/deletion analysis	
	81167	BRCA2 (BRCA2, DNA repair associated) (e.g., hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis	
	81212	BRCA1, BRCA2 breast and ovarian cancer Gene analysis, full sequence analysis and common duplication 185delAG, 538incC, 6174delT variants	
	81215	BRCA gene analysis, full sequence analysis and common duplication, Unknown familial variant	
	81216	BRCA2 gene analysis, full sequence analysis	
	81217	BRCA2 gene analysis, full sequence analysis, known familial variant	
Breast Cancer Preventive Medications - Specific for women ages 35 years and older who are at increased risk for breast cancer and low risk for adverse medical effects	Will be billed with NDC to pharmacy (script required)		Commercial- paid as a medical benefit . Self-funded- paid as a prescription benefit
Breast Cancer Screening	76641	Ultrasound breast complete	NYS Breast Mandate – May not apply to Self-funded products.
	76642	Ultrasound breast complete	NYS Breast Mandate – May not apply to Self-funded products.
	77046	Magnetic resonance imaging, breast, without contrast material; unilateral	NYS Breast Mandate – May not apply to Self-funded products.
	77047	Magnetic resonance imaging, breast, without contrast material; bilateral	NYS Breast Mandate – May not apply to Self-funded products.

	77048	Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization, and pharmacokinetic analysis), when performed; unilateral	NYS Breast Mandate – May not apply to Self-funded products.
	77049	Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization, and pharmacokinetic analysis), when performed; bilateral	NYS Breast Mandate – May not apply to Self-funded products.
	77061	Digital breast tomosynthesis; unilateral	NYS Breast Mandate – May not apply to Self-funded products.
	77062	Digital breast tomosynthesis; bilateral	NYS Breast Mandate – May not apply to Self-funded products.
	77063	Screening digital breast tomosynthesis, bilateral	The USPSTF recommends biennial screening mammography for women aged 50 to 74 years.
	77065	Mammography; unilateral	The USPSTF recommends biennial screening mammography for women aged 50 to 74 years.
	77066	Mammography; bilateral	The USPSTF recommends biennial screening mammography for women aged 50 to 74 years.
	77067	Screening mammography, bilateral (2-view film study of each breast)	The USPSTF recommends biennial screening mammography for women aged 50 to 74 years.
	G0279	Diagnostic Digital Breast Tomosynthesis Unilateral/Bilateral	The USPSTF recommends biennial screening mammography for women aged 50 to 74 years.
Breast Feeding, Primary Care Interventions to Promote	N/A		The USPSTF recommends providing interventions during pregnancy and after birth to support breastfeeding.
Breastfeeding Supplies:	A4281	Tubing for Breast Pump, replacement	
	A4282	Adapter for breast pump, replacement	
	A4283	Cap for breast pump bottle, replacement	
	A4284	Breast shield and splash protector for use with breast pump, replacement	
	A4285	Polycarbonate bottle for use with breast pump, replacement	
	A4286	Locking ring for breast pump, replacement	
	E0602	Breast pump, manual, any type	
	E0603	Breast pump, electric (AC and/or DC), any type	
	E0604	Breast pump, Hospital Grade, electric (AC and/or DC), any type	

	K1005	Disposable collection and storage bag for breast milk, any size, any type, each	New HRSA recommendation effective 1.1.23.
Breastfeeding Support and Counseling:	S9443	Lactation Classes non physician provider, per session	During pregnancy and after
Bright Futures	96110	Developmental Screening	
	96127	Emotional Behavioral Assessment	
	96160	Administration of patient-focused health risk assessment instrument (e.g., health hazard appraisal) with scoring and documentation, per standardized instrument	
	99411	Preventive medicine counseling and/or risk factor reduction intervention(s) provided to individuals in a group setting (separate procedure); approximately 30 minutes	
	99412	Preventive medicine counseling and/or risk factor reduction intervention(s) provided to individuals in a group setting (separate procedure); approximately 60 minutes	
Cervical Cancer Screening (Pap Smear)	88141	Cytopathology, cervical or vaginal (any reporting system), requiring interpretation by physician	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	88142	Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	88143	Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with manual screening and rescreening under physician supervision	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology

	88147	Cytopathology smears, cervical or vaginal; screening by automated system under physician supervision	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	88148	Cytopathology smears, cervical or vaginal; screening by automated system with manual rescreening under physician supervision	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	88150	Cytopathology; slides, cervical or vaginal; manual screening under physician supervision	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	88152	Cytopathology; slides, cervical or vaginal with manual screening and computer-assisted rescreening under physician supervision	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	88153	Cytopathology, slides, cervical or vaginal; with manual screening and rescreening under physician supervision	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	88155	Cytopathology, slides, cervical or vaginal, definitive hormone evaluation (e.g., maturation index, karyopyknotic index, estrogenic index) (List separately in addition to code[s] for other technical and interpretation services)	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology

	88164	Cytopathology, slides, cervical or vaginal (the Bethesda system) with manual screening under physician supervision	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	88165	Cytopathology, slides, cervical or vaginal (the Bethesda system) with manual screening and rescreening under physician supervision	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	88166	Cytopathology, slides, cervical or vaginal (the Bethesda system) with manual screening and computer-assisted rescreening under physician supervision	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	88167	Cytopathology, slides, cervical or vaginal (the Bethesda system); with manual screening and computer assisted rescreening using cell selection and review under physician supervision	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	88174	Cytopathology, slides, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; screening by automated system, under physician supervision	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	88175	Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review under physician supervision	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	G0101	Cervical or vaginal cancer screening; pelvic and clinical breast examination	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology

	G0123	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	G0124	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	G0141	Screening cytopathology smears, cervical or vaginal, performed by automated system, with manual rescreening, requiring interpretation by physician	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	G0143	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with manual screening and rescreening by cytotechnologist under physician supervision	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	G0144	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system, under physician supervision	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	G0145	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	G0147	Screening cytopathology smears, cervical or vaginal, performed by automated system, with manual rescreening, requiring interpretation by physician	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology

	G0148	Screening cytopathology smears, cervical or vaginal, performed by automated system with manual rescreening	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	P3000	Screening Papanicolaou smear, cervical or vaginal, up to 3 smears, by technician under physician supervision	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	P3001	Screening Papanicolaou smear, cervical or vaginal, up to 3 smears, requiring interpretation by physician	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
	Q0091	Screening Papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory	Specifically for women 21-29 years and 3 years w/cytology alone. Women ages 30 to 65 every 3 years w/cytology alone, every 5 years w/HPV testing in combination with cytology
Chlamydia and gonorrhea screening for sexually active women, including pregnant persons 24 years or younger and 25 years or older who are at increased risk for infection	86631	Antibody; Chlamydia	
	86632	Antibody; Chlamydia, glum	
	87110	Culture, chlamydia, any source	
	87270	Infectious agent antigen detection by immunofluorescent technique: Chlamydia trachomatis	
	87320	Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semi-quantitative, multiple-step method; Chlamydia trachomatis	
	87485	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, direct probe technique	
	87486	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, amplified probe technique	

	87487	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, quantification	
	87490	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, direct probe technique	
	87491	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique	
	87492	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, quantification	
	87810	Infectious agent antigen detection by immunoassay with direct optical observation; Chlamydia trachomatis	
	87800	Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; direct probe(s) technique	
	87590	Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, direct probe technique	
	87591	Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique	
	87592	Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, quantification	
	87850	Infectious agent antigen detection by immunoassay with direct optical observation; Neisseria gonorrhoeae	
Colorectal Cancer Screening, lab, Pathology, Sigmoidoscopy, and colonoscopy including preparation for the procedure	Modifier 33 or PT required		Ages 45 to 75 years
Colonoscopy Preparation	Will be billed with NDC to pharmacy (script required)		Commercial- paid as a medical benefit. Self-funded - paid as a prescription benefit.
Colonoscopy Pre-operative visits	S0285, 99201- 99205		Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
Colonoscopy and Sigmoidoscopy Procedures			
	44389	Colonoscopy through stoma; with biopsy, single or multiple	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	44392	Colonoscopy through stoma; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps or bipolar cautery	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010

	44394	Colonoscopy through stoma; with removal of tumor(s), polyp(s) or other lesion(s) by snare technique	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	44401	Colonoscopy through stoma; with removal of tumor(s), polyp(s) or other lesion(s) by snare technique	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	44404	Colonoscopy through stoma; with direct submucosal injection(s), any substance	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	44406	Colonoscopy through stoma; with endoscopic ultrasound exam, limited to the sigmoid, descending, transverse, or ascending colon and cecum and adjacent structures	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	45331	Sigmoidoscopy, flexible; with biopsy, single or multiple	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	45333	Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps or bipolar cautery	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	45335	Sigmoidoscopy, flexible; with directed submucosal injection(s), any substance	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	45338	Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	45339	Sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	45341	Sigmoidoscopy, flexible; with endoscopic ultrasound examination	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	45342	Sigmoidoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s)	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	45346	Sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s) (incl. pre- and post-dilation and guide wire passage, when performed)	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010

	45378	Colonoscopy, flexible, proximal to splenic flexure; diagnostic, with or without collection of specimen(s) by brushing or washing, with or without colon decompression (separate procedure)	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	45380	Colonoscopy, flexible, proximal to splenic flexure; with biopsy, single or multiple	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	45380	Colonoscopy, flexible, proximal to splenic flexure; with biopsy, single or multiple	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	45381	Colonoscopy, flexible, proximal to splenic flexure; with directed mucosal injection(s), any substance	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	45382	Colonoscopy, flexible, proximal to splenic flexure; with control of bleeding (i.e., injection, bipolar cautery, unipolar cautery, laser, heater probe, stapler, plasma coagulator)	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	45384	Colonoscopy, flexible, proximal to splenic flexure; with removal of tumor(s), polyp(s), or other lesion (s) by hot biopsy forceps or bipolar cautery	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	45385	Colonoscopy, flexible, proximal to splenic flexure; with removal of tumor(s), polyp(s), or other lesion (s) by snare technique	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	45388	Colonoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s) (incl. pre- and post-dilation and guide wire passage, when performed)	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	45391	Colonoscopy, flexible, proximal to splenic flexure; with endoscopic ultrasound examination	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	45392	Colonoscopy, flexible, proximal to splenic flexure; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s)	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	74263	Computed tomographic (CT) colonography, screening, including image postprocessing	
	G0104	Colorectal cancer screening; flexible colonoscopy	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010

	G0105	Colorectal cancer screening, colonoscopy on individual at high risk	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	G0120	Colorectal cancer screening; alternative to G0105, screening colonoscopy, barium enema.	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	G0121	Colorectal cancer screening: colonoscopy on individual not meeting criteria for high risk	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
Colorectal Screening Lab	81528	Oncology - colorectal screening (Cologuard)	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010
	82270	Blood, occult, by peroxidase activity (e.g., guaiac), qualitative; feces, consecutive collected specimens with single determination, for colorectal neoplasm screening (i.e., patient was provided 3 cards or single triple cards for consecutive collection)	
	82274	Blood, occult by fecal hemoglobin determination by immunoassay, qualitative, feces, 1-3 simultaneous determinations	
	G0328	Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous determinations	
Colorectal Screening Pathology	88305	Level IV Surgical pathology, gross and microscopic examination	Billed on same day as preventive colonoscopy
Colorectal Screening Sedation	99151	Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time, patient younger than 5 years of age	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010 Delivered on the same day of the colonoscopy/sigmoidoscopy
	99152	Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time, patient age 5 years or older	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010 Delivered on the same day of the colonoscopy/sigmoidoscopy

	99153	Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; each additional 15 minutes intra-service time	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010 Delivered on the same day of the colonoscopy/sigmoidoscopy
	99156	Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; initial 15 minutes of intra-service time, patient age 5 years or older	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010 Delivered on the same day of the colonoscopy/sigmoidoscopy
	99157	Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; each additional 15 minutes of intra-service time	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010 Delivered on the same day of the colonoscopy/sigmoidoscopy
	00812	Anesthesia for lower intestinal endoscopic procedures, endoscope introduced distal to duodenum; screening colonoscopy	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010 Delivered on the same day of the colonoscopy/sigmoidoscopy
	G0500	Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate)	Ages 45 to 75 years with Modifier 33 or diagnosis codes Z12.10, Z12.11. Z12.12, Z80.0, Z83.71. Z86.010 Delivered on the same day of the colonoscopy/sigmoidoscopy
Congenital Hypothyroidism Screening	Global to Newborn DRG		
Contraceptive Methods and Counseling:	11976	Removal, implantable contraceptive capsule	
	57170	Diaphragm or cervical cap fitting with instructions	
	58300	Insertion of intrauterine device (IUD)	
	58301	Removal of intrauterine device (IUD)	

	58565	Hysteroscopy with bilateral fallopian tube cannulation to induce occlusion by placement of permanent implants	
	58600	Ligation or transection of fallopian tube (s), abdominal or vaginal approach, unilateral or bilateral	
	58605	Ligation or transection of fallopian tube (s), abdominal or vaginal approach, unilateral or bilateral, during same hospitalization (separate procedure)	
	58611	Ligation or transection of fallopian tube(s), when done at the time of cesarean delivery or intra-abdominal surgery (not a separate procedure)	
	58615	Occlusion of fallopian tube(s) by device (e.g., band, clip, Falope ring) vaginal or suprapubic approach	
	58670	Laparoscopy, with fulguration of oviducts (with or without transection)	
	58671	Laparoscopy, with occlusion of oviducts by device (e.g., band, clip, or Falope ring)	
	Will be billed with NDC to pharmacy (script required).	Cervical cap for contraceptive (A4261)	Commercial- paid as a medical benefit . Self funded paid as prescription benefit.
	Will be billed with NDC to pharmacy (script required).	Diaphragm for contraceptive (A4266)	Commercial- paid as a medical benefit . Self funded paid as prescription benefit.
	J1050	Injection, medroxyprogesterone acetate, 1 mg.	With Diagnosis Codes Z30, Z30.0, Z30.1. Z30.11, Z30.12, Z30.13. Z30.14, Z30.430, Z30.432, Z30.018, Z30.019, Z30.02, Z30.09, Z30.2, Z30.4, Z30.41, Z30.42, Z30.43, Z30.430, Z30.431, Z30.432, Z30.433, Z30.49, Z30.8, Z30
	J1056	Injection, medroxyprogesterone acetate / estradiol cypionate, 5mg / 25mg	
	J7300	Intrauterine copper contraceptive (use this code for Paragard)	
	J7301	Levonorgestrel Releasing Intrauterine Contraceptive System (Skyla)- 13.5 MG	
	99201 - 99215	Contraceptive Management Counseling	With Diagnosis codes Z30, Z30.0, Z30.1. Z30.11, Z30.12, Z30.13. Z30.14, Z30.430, Z30.432, Z30.018, Z30.019, Z30.02, Z30.09, Z30.2, Z30.4, Z30.41, Z30.42, Z30.43, Z30.430, Z30.431, Z30.432, Z30.433, Z30.49, Z30.8, Z30.9

		Levonorgestrel-releasing intrauterine contraceptive system, 52 mg (use this code for Mirena) (J7302)	
	Will be billed with NDC to pharmacy (script required).	Contraceptive supply, hormone containing vaginal ring each (use this code for NuvaRing Vaginal Ring) (J7303)	Commercial- paid as a medical benefit . Self funded paid as prescription benefit.
	Will be billed with NDC to pharmacy (script required).	Contraceptive supply, hormone containing patch, each	Commercial- paid as a medical benefit . Self funded paid as prescription benefit.
	Will be billed with NDC to pharmacy (script required).	Etonogestrel (contraceptive) implant system, including implant and supplies (use this code for Nexplanon) J7307	Commercial- paid as a medical benefit . Self funded paid as prescription benefit.
Condoms – Male and Female	Will be billed with NDC to pharmacy		Commercial- paid as a medical benefit
			Self-funded - paid as a prescription benefit
Oral contraceptives	Will be billed with NDC to pharmacy (script required)		Commercial- paid as a medical benefit . Self funded paid as prescription benefit.
Dental Caries in Preschool Children, Prevention	Part of office visit		Deleted 1. 1.2023
Dental Caries in Children from birth through age 5 years: Screening: children from birth through age 5 years – Fluoride Supplement	Will be billed with NDC to pharmacy (script required)		The USPSTF recommends that primary care clinicians prescribe oral fluoride supplementation starting at age 6 months for children whose water supply is deficient in fluoride
			Commercial- paid as a medical benefit . Self funded paid as prescription benefit.
Dental Caries in Children from birth through age 5 years: Screening: children from birth through age 5 years – Fluoride varnish	99188	Application of topical fluoride varnish by a physician or other qualified health care professional	The USPSTF recommends that primary care clinicians apply fluoride varnish to the primary teeth of all infants and children starting at the age of primary tooth eruption.

	0792T	Application of silver diamine fluoride 38%, by a physician or other qualified health care professional	The USPSTF recommends that primary care clinicians apply fluoride varnish to the primary teeth of all infants and children starting at the age of primary tooth eruption.
Depression in Adults: Screening; general adult population, including pregnant and postpartum women	99401	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual (separate procedure) approximately 15 minutes	The USPSTF recommends screening for depression in the general adult population, including pregnant and postpartum women. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.
Depression in Children and Adolescents: Screening: adolescents aged 12 to 18 years	99402	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual, approximately 30 minutes	The USPSTF recommends screening for major depressive disorder (MDD) in adolescents aged 12 to 18 years.
	99403	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual, approximately 45 minutes	The USPSTF recommends screening for major depressive disorder (MDD) in adolescents aged 12 to 18 years.
	99404	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual, approximately 60 minutes	The USPSTF recommends screening for major depressive disorder (MDD) in adolescents aged 12 to 18 years.
	G0444	Annual depression screening, 15 minutes	The USPSTF recommends screening for major depressive disorder (MDD) in adolescents aged 12 to 18 years.
Screening for suicide risk for ages 12 – 21	Part of office visit		New HRSA recommendation effective 1.1.23.
Diabetic Shoes			Not covered as preventive for Commercial Standard plans and not covered for Essential Plans and certain Self-funded plans.
	A5500	For diabetics only, fitting (including follow-up), custom preparation and supply of off-the-shelf depth-inlay shoe manufactured to accommodate multi-density insert (s), per shoe	Diagnosis codes E08.32 -E13.9

	A5501	For diabetics only, fitting (including follow-up), custom preparation and supply of shoe molded from cast (s) of patient's foot (custom molded shoe), per shoe	Diagnosis codes E08.32 -E13.9
	A5503	For diabetics only, modification (including fitting) of off-the-shelf depth-inlay shoe or custom-molded shoe with roller or rigid rocker bottom, per shoe	Diagnosis codes E08.32 -E13.9
	A5504	For diabetics only, modification (including fitting) of off-the-shelf depth-inlay shoe or custom-molded shoe with wedge (s), per shoe	Diagnosis codes E08.32 -E13.9
	A5505	For diabetics only, modification (including fitting) of off-the-shelf depth-inlay shoe or custom-molded shoe with metatarsal bar, per shoe	Diagnosis codes E08.32 -E13.9
	A5506	For diabetics only, modification (including fitting) of off-the-shelf depth-inlay shoe or custom-molded shoe with off-set heel (s), per shoe	Diagnosis codes E08.32 -E13.9
	A5507	For diabetics only, not otherwise specified modification (including fitting) of off-the-shelf depth-inlay shoe or custom-molded shoe, per shoe.	Diagnosis codes E08.32 -E13.9
	A5508	For diabetics only, deluxe feature of off-the-shelf depth-inlay shoe or custom-molded shoe, per shoe.	Diagnosis codes E08.32 -E13.9
	A5510	For diabetics only, direct formed, compression molded to patient's foot without external heat source, multiple density insert (s) prefabricated, per shoe	Diagnosis codes E08.32 -E13.9

	A5512	For diabetics only, direct formed, compression molded to patient's foot without external heat source, multiple density insert (s) prefabricated, per shoe	Diagnosis codes E08.32 -E13.9
	A5513	For diabetics only, multiple density insert, custom molded from model of patient's foot, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each	Diagnosis codes E08.32 -E13.9
	A5514	For diabetics only, multiple density insert, made by direct carving with cam technology from a rectified cad model created from a digitized scan of the patient, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each	Diagnosis codes E08.32 -E13.9
	K0903	For diabetics only, multiple density insert, made by direct carving with cam technology from a rectified cad model created from a digitized scan of the patient	Diagnosis codes E08.32 -E13.9
Diabetic Supplies			Covered as preventive by FEHB effective January 1, 2023.
			Not Preventive for Commercial Standard plans and Essential Plans
	A4222	Infusion supplies for external drug pump, per cassette or bad	Not Preventive for Commercial Standard plans and Essential Plans
	A4224	Supplies for maintenance of insulin infusion catheter,	Not Preventive for Commercial Standard plans and Essential Plans
	A4225	Supplies for external insulin infusion pump, syringe type cartridge, sterile	Not Preventive for Commercial Standard plans and Essential Plans

	A4226	Supplies for maintenance of insulin infusion pump with dosage rate adjustment using therapeutic continuous glucose sensing	Not Preventive for Commercial Standard plans and Essential Plans
	A4230	Infusion set for external insulin pump, non-needle cannula type	Not Preventive for Commercial Standard plans and Essential Plans
	A4231	Infusion set for external insulin pump, needle type	Not Preventive for Commercial Standard plans and Essential Plans
	A4232	Syringe with needle for external insulin pump, sterile, 3 cc	Not Preventive for Commercial Standard plans and Essential Plans
	A4233	replacement battery, alkaline (other than J cell), for use with medically necessary home blood glucose monitor owned by patient, each	Not Preventive for Commercial Standard plans and Essential Plans
	A4234	Replacement battery, alkaline, j cell, for use with medically necessary home blood glucose monitor owned by patient, each	Not Preventive for Commercial Standard plans and Essential Plans
	A4235	Replacement battery, lithium, for use with medically necessary home blood glucose monitor owned by patient, each	Not Preventive for Commercial Standard plans and Essential Plans
	A4236	Replacement battery, silver oxide, for use with medically necessary home blood glucose monitor owned by patient, each.	Not Preventive for Commercial Standard plans and Essential Plans
	A4250	Urine test or reagent strips or tablets	Not Preventive for Commercial Standard plans and Essential Plans
	A4252	Blood ketone test or reagent strip	Not Preventive for Commercial Standard plans and Essential Plans
	A4253	Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips	Not Preventive for Commercial Standard plans and Essential Plans
	A4256	Normal, low and high calibrator solution / chips	Not Preventive for Commercial Standard plans and Essential Plans
	A4257	Replacement lens shield cartridge for use with laser skin piercing device,	Not Preventive for Commercial Standard plans and Essential Plans
	A4258	Spring-powered device for lancet, each.	Not Preventive for Commercial Standard plans and Essential Plans
	A4259	Lancets, per box of 100	Not Preventive for Commercial Standard plans and Essential Plans
	A4772	Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips	Not Preventive for Commercial Standard plans and Essential Plans
	A6257	Description: Transparent film, sterile, 16 sq. in. or less, each dressing	Not Preventive for Commercial Standard plans and Essential Plans

	A6258	Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in	Not Preventive for Commercial Standard plans and Essential Plans
	A6259	Transparent film, sterile, more than 48 sq. in.,	Not Preventive for Commercial Standard plans and Essential Plans
	A9274	External ambulatory insulin delivery system, disposable, each	Not Preventive for Commercial Standard plans and Essential Plans
	K0553	Supply allowance for therapeutic continuous glucose monitor (cgm)	Not Preventive for Commercial Standard plans and Essential Plans
	K0601	Replacement battery for external infusion pump owned by patient, silver oxide, 1.5 volt, each	Not Preventive for Commercial Standard plans and Essential Plans
	K0602	Replacement battery for external infusion pump owned by patient, silver oxide, 3 volt, each	Not Preventive for Commercial Standard plans and Essential Plans
	K0603	Replacement battery for external infusion pump owned by patient, alkaline, 1.5 volt,	Not Preventive for Commercial Standard plans and Essential Plans
	K0604	Replacement battery for external infusion pump owned by patient, lithium, 3.6 volt,	Not Preventive for Commercial Standard plans and Essential Plans
	K0605	Replacement battery for external infusion pump owned by patient, lithium, 4.5-volt, e	Not Preventive for Commercial Standard plans and Essential Plans
	S5560	Insulin delivery device, reusable pen; 1.5 ml size	Not Preventive for Commercial Standard plans and Essential Plans
	S5561	Insulin delivery device, reusable pen; 3 ml size.	Not Preventive for Commercial Standard plans and Essential Plans
	S5565	Insulin cartridge for use in insulin delivery device other than pump; 150 units	Not Preventive for Commercial Standard plans and Essential Plans
	S5566	Insulin cartridge for use in insulin delivery device other than pump; 300 units	Not Preventive for Commercial Standard plans and Essential Plans
	S5570	Insulin delivery device, disposable pen (including insulin); 1.5 ml size	Not Preventive for Commercial Standard plans and Essential Plans
	S5571	Insulin delivery device, disposable pen (including insulin); 3 ml size	Not Preventive for Commercial Standard plans and Essential Plans
	S8490	Insulin syringes (100 syringes, any size)	Not Preventive for Commercial Standard plans and Essential Plans
	T1999	Miscellaneous therapeutic items and supplies	Not Preventive for Commercial Standard plans and Essential Plans

Diabetes Prevention Program	0403T with no modifier	Preventive behavior change, intensive program of prevention of diabetes using a standardized diabetes prevention program curriculum, provided to individuals in a group setting, minimum 60 minutes, per day	
	0403T with modifier GQ	Preventive behavior change, intensive program of prevention of diabetes using a standardized diabetes prevention program curriculum, provided to individuals in a group setting, minimum 60 minutes, per day	Brook+ is not participating with all Self-funded plans.
	0488T with modifier TF and Modifier SE	Preventive behavior change, online/electronic intensive program of prevention of diabetes using a standardized diabetes prevention program curriculum, provided to an individual, per 30 days	Brook+ is not participating with all Self-funded plans.
	0488T with modifier TG and Modifier SE	Preventive behavior change, online/electronic intensive program of prevention of diabetes using a standardized diabetes prevention program curriculum, provided to an individual, per 30 days	Brook+ is not participating with all Self-funded plans.
	0488T with Modifier TS and Modifier SE	Preventive behavior change, online/electronic intensive program of prevention of diabetes using a standardized diabetes prevention program curriculum, provided to an individual, per 30 days	Brook+ is not participating with all Self-funded plans.
	0488T-with modifier TT and Modifier SE	Preventive behavior change, online/electronic intensive program of prevention of diabetes using a standardized diabetes prevention program curriculum, provided to an individual, per 30 days	Brook+ is not participating with all Self-funded plans.

	G9880	Provider incentive payment for Members who have achieved at least 5% weight loss from their baseline. This is a one-time payment available when the Member first achieves the 5% weight loss from baseline.	
Falls prevention in Community-Dwelling Older Adults: Interventions: adults 65 years or older	97110 97112 97113 97116 97139,97150, 97161, 9716,3 97164	Physical Therapy	The USPSTF recommends exercise interventions to prevent falls in community-dwelling adults 65 years or older who are at increased risk for falls.
	97530, G0157		
	G0159		With diagnosis codes below in primary position: R26.1, R26.2, R26.81, R26.89, R29.6. R54, Z91.81
Folic Acid for the Prevention of Neural Tube defects: - Daily Supplement	Will be billed with NDC to pharmacy (script required)		The USPSTF recommends that all women who are planning or capable of pregnancy take a daily supplement containing 0.4 to 0.8 mg (Specific for all women capable of pregnancy take a supplement containing 0.4 to 0.8 mg of folic acid.
			Commercial- paid as a medical benefit
			Self-funded - paid as a prescription benefit
General Health Panel/Basic Metabolic Panel	80048	Basic metabolic panel (calcium, total)	
	80050	General health panel	
Gestational Diabetes: Screening	82947	Glucose, quantitative, blood (except reagent strip)	The USPSTF recommends screening for gestational diabetes in asymptomatic pregnant persons at 24 weeks of gestation or after.
	82948	Glucose, blood, reagent strip	The USPSTF recommends screening for gestational diabetes in asymptomatic pregnant persons at 24 weeks of gestation or after
	82951	Glucose tolerance test, 3 specimens (includes glucose)	The USPSTF recommends screening for gestational diabetes in asymptomatic pregnant persons at 24 weeks of gestation or after

	82951	Glucose tolerance test, 3 specimens (includes glucose)	The USPSTF recommends screening for gestational diabetes in asymptomatic pregnant persons at 24 weeks of gestation or after
	83036	Hemoglobin; glycosylated (A1C)	The USPSTF recommends screening for gestational diabetes in asymptomatic pregnant persons at 24 weeks of gestation or after
Gonorrhea, Prophylactic Medication	Global to Newborn DRG		
Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults with Cardiovascular Risk Factors: Behavioral Counseling Interventions			
Healthy Weight and Weight Gain in Pregnancy: Behavioral Counseling Interventions: pregnant persons			
	97802	Medical nutrition therapy; initial assessment and intervention, individual, face to face with patient, each 15 minutes	
	97803	Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes	
	97804	Medical nutrition therapy; group (2 or more individuals), each 30 minutes	
	99401	Preventive medicine counseling and/or risk factor reduction intervention (s) provided to an individual (separate procedure); approximately 15 minutes	
	99402	Preventive medicine counseling and/or risk factor reduction intervention (s) provided to an individual, (separate procedure); approximately 30 minutes	
	99403	Preventive medicine counseling and/or risk factor reduction intervention (s) provided to an individual (separate procedure); approximately 45 minutes	

	99404	Preventive medicine counseling and/or risk factor reduction intervention (s) provided to an individual (separate procedure) approximately 60 minutes	
	G0108	Diabetes outpatient self-management training services, individual, per 30 minutes	Not Preventive for Commercial Standard plans and Essential Plans
	G0109	Diabetes outpatient self-management training services, group session (2 or more) per 30 minutes	Not Preventive for Commercial Standard plans and Essential Plans
	G0270	Medical nutrition therapy: reassessment and subsequent interventions following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face to face with the patient each 15 minutes	
	G0271	Medical nutrition therapy: reassessment and subsequent interventions following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face to face with the patient each 30 minutes	
	G0446	Intensive behavioral therapy to reduce cardiovascular disease risk, individual, face-to-face, bi-annual, 15 minutes	
	G0473	Face-to-face Behavioral Counseling Obesity Group 30 minutes	
	S9140	Diabetic Management Program, follow-up visit to non-MD provider	Not Preventive for Commercial Standard plans and Essential Plans

	S9141	Diabetic Management Program, follow-up visit to MD provider	Not Preventive for Commercial Standard plans and Essential Plans
	S9452	Nutrition classes, nonphysician provider, per session	
	S9455	Diabetic management program, group session	
	S9460	Diabetic management program, nurse visit	Not Preventive for Commercial Standard plans and Essential Plans
	S9465	Diabetic management program, dietitian visit	Not Preventive for Commercial Standard plans and Essential Plans
	S9470	Nutrition counseling, dietitian visit	
Hearing Loss Screening for Newborns	Global to Newborn DRG		
Hepatitis B Virus Infection, Screening - Specifically for adolescents and adults at increased risk and all pregnant women at first prenatal visit	86704	Hepatitis B core antibody (HBcAb); total	With diagnosis codes O09.00, O30.001- O30.93, O31.10X1 - O31.8X99, Z01.411- Z01.42, Z11.3, Z11.59, Z20.2, Z33.1, Z34.00- Z34.93, Z36.0 - Z36.9, Z57.8.
	86705	Hepatitis B core antibody (HBcAb); IgM antibody	With diagnosis codes O09.00, O30.001- O30.93, O31.10X1 - O31.8X99, Z01.411- Z01.42, Z11.3, Z11.59, Z20.2, Z33.1, Z34.00- Z34.93, Z36.0 - Z36.9, Z57.8.
	86706	Hepatitis B surface antibody (HBsAb)	With diagnosis codes O09.00, O30.001- O30.93, O31.10X1 - O31.8X99, Z01.411- Z01.42, Z11.3, Z11.59, Z20.2, Z33.1, Z34.00- Z34.93, Z36.0 - Z36.9, Z57.8.

	86707	Hepatitis Be antibody (HBeAb)	With diagnosis codes O09.00, O30.001- O30.93, O31.10X1 - O31.8X99, Z01.411- Z01.42, Z11.3, Z11.59, Z20.2, Z33.1, Z34.00- Z34.93, Z36.0 - Z36.9, Z57.8.
	87517	Hepatitis B quantification	With diagnosis codes O09.00, O30.001- O30.93, O31.10X1 - O31.8X99, Z01.411- Z01.42, Z11.3, Z11.59, Z20.2, Z33.1, Z34.00- Z34.93, Z36.0 - Z36.9, Z57.8.
	87340	Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semi-quantitative, multiple step method, hepatitis B surface antigen (HBsAg)	With diagnosis codes O09.00, O30.001- O30.93, O31.10X1 - O31.8X99, Z01.411- Z01.42, Z11.3, Z11.59, Z20.2, Z33.1, Z34.00- Z34.93, Z36.0 - Z36.9, Z57.8.
	87341	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; hepatitis B surface antigen (HBsAg) neutralization	With diagnosis codes O09.00, O30.001- O30.93, O31.10X1 - O31.8X99, Z01.411- Z01.42, Z11.3, Z11.59, Z20.2, Z33.1, Z34.00- Z34.93, Z36.0 - Z36.9, Z57.8.
	G0499	Hepatitis B screening in non-pregnant high-risk individual	
Hepatitis C Screening	86803	Hepatitis C Antibody	Specifically for all adults ages 18 to 79 years
	86804	Hepatitis C Confirmatory Test	Specifically for all adults ages 18 to 79 years
HIV Screening	86689	Antibody; HTLV or HIV antibody, confirmatory test (e.g., Western Blot)	Specific for adolescents and adults ages 13 to 65 years and younger adolescents and older adults at increased risk. Also, all pregnant women including those who present in labor or at delivery whose HIV status is unknown .

	86701	Antibody; HIV-1	Specific for adolescents and adults ages 13 to 65 years and younger adolescents and older adults at increased risk. Also, all pregnant women including those who present in labor or at delivery whose HIV status is unknown .
	86702	Antibody; HIV-2	Specific for adolescents and adults ages 13 to 65 years and younger adolescents and older adults at increased risk. Also, all pregnant women including those who present in labor or at delivery whose HIV status is unknown .
	86703	Antibody; HIV-1 and HIV-2, single assay	Specific for adolescents and adults ages 13 to 65 years and younger adolescents and older adults at increased risk. Also, all pregnant women including those who present in labor or at delivery whose HIV status is unknown .
	87389	HIV-1 antigen, with HIV-1 and HIV-2 antibodies, single result	Specific for adolescents and adults ages 13 to 65 years and younger adolescents and older adults at increased risk. Also, all pregnant women including those who present in labor or at delivery whose HIV status is unknown .

	87390	Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semi-quantitative, multiple step method, HIV-1	Specific for adolescents and adults ages 13 to 65 years and younger adolescents and older adults at increased risk. Also, all pregnant women including those who present in labor or at delivery whose HIV status is unknown .
	87391	Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semi-quantitative, multiple step method; HIV-2	Specific for adolescents and adults ages 13 to 65 years and younger adolescents and older adults at increased risk. Also, all pregnant women including those who present in labor or at delivery whose HIV status is unknown .
	87534	Infectious agent detection by nucleic acid (DNA or RNA); HIV 1 Direct Probe technique	Specific for adolescents and adults ages 13 to 65 years and younger adolescents and older adults at increased risk. Also, all pregnant women including those who present in labor or at delivery whose HIV status is unknown .
	87535	Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, amplified probe quantification	Specific for adolescents and adults ages 13 to 65 years and younger adolescents and older adults at increased risk. Also, all pregnant women including those who present in labor or at delivery whose HIV status is unknown .
	87536	Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification	Specific for adolescents and adults ages 13 to 65 years and younger adolescents and older adults at increased risk. Also, all pregnant women including those who present in labor or at delivery whose HIV status is unknown .

	87537	Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, Direct probe technique	Specific for adolescents and adults ages 13 to 65 years and younger adolescents and older adults at increased risk. Also, all pregnant women including those who present in labor or at delivery whose HIV status is unknown .
	87538	Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, amplified probe technique	Specific for adolescents and adults ages 13 to 65 years and younger adolescents and older adults at increased risk. Also, all pregnant women including those who present in labor or at delivery whose HIV status is unknown .
	87539	Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, quantification	Specific for adolescents and adults ages 13 to 65 years and younger adolescents and older adults at increased risk. Also, all pregnant women including those who present in labor or at delivery whose HIV status is unknown .
	G0432	Infectious agent antibody detection by enzyme immunoassay technique, HIV-1 and/or HIV-2 screening	Specific for adolescents and adults ages 13 to 65 years and younger adolescents and older adults at increased risk. Also, all pregnant women including those who present in labor or at delivery whose HIV status is unknown .
	G0433	Infectious agent antibody detection by enzyme-linked immunosorbent assay (ELISA) technique, HIV-1 and/or HIV-2 screening	Specific for adolescents and adults ages 13 to 65 years and younger adolescents and older adults at increased risk. Also, all pregnant women including those who present in labor or at delivery whose HIV status is unknown .
	G0435	Infectious agent antibody detection by rapid antibody tests of oral mucosa transudate, HIV-1 or HIV-2 screening technique, HIV-1 or HIV-2	Specific for adolescents and adults ages 13 to 65 years and younger adolescents and older adults at increased risk. Also, all pregnant women including those who present in labor or at delivery whose HIV status is unknown .
	G0475	HIV antigen/antibody, combination assay, screening	Specific for adolescents and adults ages 13 to 65 years and younger adolescents and older adults at increased risk. Also, all pregnant women including those who present in labor or at delivery whose HIV status is unknown .

	S3645	HIV-1 Antibody testing of oral mucosal transudate	Specific for adolescents and adults ages 13 to 65 years and younger adolescents and older adults at increased risk. Also, all pregnant women including those who present in labor or at delivery whose HIV status is unknown .
HIV Counseling	99401	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual approximately 15 minutes	
	99402	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual, approximately 30 minutes	
	99403	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual, approximately 45 minutes	
	99404	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual, approximately 60 minutes	
HIV pre-exposure	Will be billed with NDC to pharmacy (script required)		Commercial- paid as a medical benefit
Offer preexposure prophylaxis (PrEP) with effective antiretroviral therapy to those at high risk for HIV			Self-funded - paid as a prescription benefit
HIV testing	Claims billed with Diagnosis code Z20.6		
HPV Screening	87623	Human Papillomavirus (HPV), low-risk types (egg. 6,	
	87624	Human Papillomavirus (HPV), high risk types (egg. 16, 18, 31,33,35,39,45,51,52,56, 58, 59, 68)	
	87625	Human Papillomavirus (HPV), types 16 and 18 only, include type 45, if performed.	

	G0476	Infectious agent detection by nucleic acid (DNA or RNA); human papillomavirus (HPV), high-risk types for cervical cancer screening, must be performed in addition to pap smear	
	0500T	Infectious agent detection by nucleic acid (DNA or RNA), human papillomavirus (HPV) for five or more separately reported high-risk HPV types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) (i.e., genotyping)	
Hypertension in Adults; Screening; adults 18 years or older without known hypertension	Part of office visit		The USPSTF recommends screening for hypertension in adults 18 years or older with office blood pressure measurement (OBPM). The USPSTF recommends obtaining blood pressure measurements outside of the clinical setting for diagnostic confirmation before starting treatment.
Interpersonal and domestic violence counseling move down	99401	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual (separate procedure) approximately 15 minutes	
	99402	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual, approximately 30 minutes	
	99403	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual, approximately 45 minutes	
	99404	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual, approximately 60 minutes	

Intimate Partner Violence, Elder Abuse and Abuse of Vulnerable Adults; Screening- Previously known as Interpersonal and domestic violence screening	Part of office visit		The USPSTF recommends that clinicians screen for intimate partner violence in women of reproductive age and provide or refer women who screen positive to ongoing support services.
Iron Deficiency in Pregnant Women Testing	85014	Blood Count; hematocrit (Hct)	Primary Pregnancy diagnosis
	85018	Blood Count, hemoglobin (Hgb)	Primary Pregnancy diagnosis
Latent Tuberculosis Infection Screening: asymptomatic adults at increased risk of infection	86480	Tuberculosis test, cell mediated immunity antigen response measurement	
	86481	Tuberculosis test, enumeration of gamma interferon-producing T -cells in cell suspension	
	86580	Skin test; tuberculosis, intradermal	
Lead Screening	83655	Lead	
Laboratory Services	80055	Obstetric panel	
	80081	Obstetric panel (includes HIV testing)	
	86762	Antibody, rubella	
Lipid Screening (Cardiovascular Screening)	80061	Lipid panel. This panel must include the following: Cholesterol, serum, total (82465), Lipoprotein, direct measurement, high density cholesterol (HDL cholesterol) (83718), triglycerides (84478)	Identification of dyslipidemia and calculation of 10-year risk of a Cardiovascular event requires universal lipids screening in adults ages 40-75 years
	82465	Cholesterol, serum or whole blood total	Identification of dyslipidemia and calculation of 10-year risk of a Cardiovascular event requires universal lipids screening in adults ages 40-75 years

	83718	Lipoprotein, direct measurement, high density cholesterol	Identification of dyslipidemia and calculation of 10-year risk of a Cardiovascular event requires universal lipids screening in adults ages 40-75 years
	84478	Triglycerides	Identification of dyslipidemia and calculation of 10-year risk of a Cardiovascular event requires universal lipids screening in adults ages 40-75 years
Lung Cancer: Screening adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years -Low Dose CT Lung Screening	71271	Special screening for malignant neoplasms - respiratory organs	
	G0296	Visit to determine Low Dose CT eligibility	
	G0297	Low Dose CT for lung cancer screen	
Major Depressive Disorder Screening for Children and Adolescents	99401	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual, approximately 15 minutes	Specific to ages 12 to 18 years
	99402	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual, approximately 30 minutes	Specific to ages 12 to 18 years
	99403	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual, approximately 45 minutes	Specific to ages 12 to 18 years
	99404	Preventive medicine and/or risk factor reduction intervention provided to an individual, approximately 60	Specific to ages 12 to 18 years
Obesity Screening in Adults, Children & Adolescents	99401	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual, approximately 15 minutes	
	99402	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual, approximately 30 minutes	
	99403	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual, approximately 45 minutes	

	99404	Preventive medicine and/or risk factor reduction intervention provided to an individual, approximately 60 minutes	
	G0447	Face-to-face behavioral counseling for obesity, 15 minutes	
	G0449	Annual Face-to-face obesity screening, 15 minutes	
Perinatal depression: Preventive Interventions: pregnant and postpartum persons	96161	Administration of caregiver-focused health risk assessment instrument for the benefit of the patient with scoring and documentation per standardized instrument	Primary Pregnancy diagnosis
Phenylketonuria Screening (Children)	Part of newborn DRG		
	S3650	Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and	Under 1 years of age
	84030	Phenylalanine (PKU), blood	Under 1 years of age
Prediabetes and Type 2 Diabetes: Screening; asymptomatic adults aged 35 to 70 years who have overweight or obesity	82947	Glucose, quantitative, blood (except reagent strip)	The USPSTF recommends screening for prediabetes and Type 2 diabetes in adults aged 35 to 70 years who have overweight or obesity. Clinicians should offer or refer patients with prediabetes to effective preventive interventions.
	82948	Glucose, blood, reagent strip	The USPSTF recommends screening for prediabetes and Type 2 diabetes in adults aged 35 to 70 years who have overweight or obesity. Clinicians should offer or refer patients with prediabetes to effective preventive interventions.

	82950	Glucose, post glucose dose (includes glucose)	The USPSTF recommends screening for prediabetes and Type 2 diabetes in adults aged 35 to 70 years who have overweight or obesity. Clinicians should offer or refer patients with prediabetes to effective preventive interventions.
	82951	Glucose tolerance test, 3 specimens (includes glucose)	The USPSTF recommends screening for prediabetes and Type 2 diabetes in adults aged 35 to 70 years who have overweight or obesity. Clinicians should offer or refer patients with prediabetes to effective preventive interventions.
	83036	Hemoglobin; glycosylated (A1C)	The USPSTF recommends screening for prediabetes and Type 2 diabetes in adults aged 35 to 70 years who have overweight or obesity. Clinicians should offer or refer patients with prediabetes to effective preventive interventions.
Prenatal Visit and one Post-Partum Visit	59425	Antepartum care only; 4 -6 visits	Primary diagnosis: Pregnancy
	59426	Antepartum care only; 7 or more visits	
	59430	Postpartum care only (separate procedure)	ACOG recommends two post-partum visits: within 3 weeks of delivery and then by 12 weeks
	0500F	Initial prenatal care visit (report at first encounter with health care professional providing obstetrical care. Report also date of visit and, in a separate field, the date of the last menstrual period)	
	0501F	Prenatal flow sheet documented in medical record by first prenatal visit (documentation includes at minimum blood pressure, weight, urine protein, uterine size, fetal heart tones, and estimated date of delivery). Report also: date of visit and, in a separate field, the date of the last menstrual period)	
	0502F	Subsequent prenatal care visit	
	0503F	Postpartum care visit	

Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis: persons at high risk of HIV acquisition	Will be billed with NDC to pharmacy (script required)		Commercial- paid as a medical benefit
			Self-funded - paid as a prescription benefit
Prostate Specific Antigen (PSA)	84152	Prostate specific antigen (PSA) complexed (direct	
	84153	Prostate specific antigen (PSA) total	
	84154	Prostate specific antigen (PSA) free)	
	G0103	Prostate cancer screening; prostate specific antigen (PSA)	
Psychosocial/behavioral assessment coverage was expanded to behavioral/social/emotional screening for newborn to 21 years of age	Part of office visit		New HRSA recommendation effective 1.1.23
RH (D) Incompatibility Screening in Pregnancy Women	86901	Blood typing; RH (D)	During the first visit for all pregnant women. Then repeated testing for all unsensitized Rh(D)-negative women at 24-28 wks. Gestation.
Screening for Anxiety, behavioral/social/emotional Screening for newborn to 21 years of age	96127	Brief emotional/behavioral assessment	Diagnosis code Z13.39
Screening for Urinary Incontinence	Part of office visit		
Sexually Transmitted Infections Counseling	99401	Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 15 minutes	Behavioral counseling for all sexually active adolescents and adults at increased risk

	99402	Preventive medicine counseling and/or risk factor reduction(s) provided to an individual (separate procedure); approximately 30 minutes	Behavioral counseling for all sexually active adolescents and adults at increased risk
	99403	Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 45 minutes	Behavioral counseling for all sexually active adolescents and adults at increased risk
	99404	Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure) ; approximately 60 minutes	Behavioral counseling for all sexually active adolescents and adults at increased risk
	G0445	High intensity behavioral counseling to prevent sexually transmitted infection; face-to-face individual, includes education, skills training, and guidance on how to change sexual behavior; performed semi-annually, 30 minutes	Behavioral counseling for all sexually active adolescents and adults at increased risk
	G0450	Screening for sexually transmitted infection, includes laboratory tests for chlamydia, gonorrhea, syphilis, and hepatitis B	Behavioral counseling for all sexually active adolescents and adults at increased risk
	86593	Syphilis test, non-treponemal antibody; quantitative (e.g., VDRL, RPR, ART)	Behavioral counseling for all sexually active adolescents and adults at increased risk
Skin Cancer Prevention: Behavioral Counseling: young adults, adolescents, children, and parents of young children	No specific, part of preventive visits		
Smoking Cessation Intervention-Pharmacotherapy	Will be billed with NDC to pharmacy (script required)		Specific to adults and non-pregnant women with FDA approved pharmacotherapy
			Commercial- paid as a medical benefit

			Self-funded - paid as a prescription benefit
			Exception: Zyban – requires Rx benefit for Commercial
Statin preventive Medication - Adults 40 - 75 years with no history of CVD, 1 or more CVD risk factors and a calculated 10-year CVS event risk of 10% or greater	Will be billed with NDC to pharmacy (script required)		Identification of dyslipidemia and calculation of 10-year risk of a Cardiovascular event requires universal lipids screening in adults ages 40-75 years
			Commercial- paid as a medical benefit
			Self-funded - paid as a prescription benefit
Syphilis Screening	86592	Syphilis test, non-treponemal antibody; qualitative (e.g., VDRL, RPR, ART)	Specific to non-pregnant adults & adolescents at increased risk and early screening for all pregnant women
	86593	Syphilis test, non-treponemal antibody; quantitative	Specific to non-pregnant adults & adolescents at increased risk and early screening for all pregnant women
	86780	Antibody; Treponema pallidum	Specific to non-pregnant adults & adolescents at increased risk and early screening for all pregnant women
	87660	Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, direct probe technique	Specific to non-pregnant adults & adolescents at increased risk and early screening for all pregnant women

	87661	Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique	Specific to non-pregnant adults & adolescents at increased risk and early screening for all pregnant women
Tobacco Smoking Cessation in Adults including Pregnant Persons: Interventions; pregnant persons	99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	
	99407	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	
Tobacco Use in Children and Adolescents: school aged children and adolescents who have not started to use tobacco	99401	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual (separate procedure) approximately 15 minutes	According to USPSTF this includes e-cigarette and any form of tobacco (smokeless, hookah, vaping use by school aged children and adolescents younger than 18 including pregnant persons
	99402	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual, approximately 30 minutes	
	99403	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual, approximately 45 minutes	
	99404	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual, approximately 60 minutes	
Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions; adults 18 years or older, including pregnant women		The USPSTF recommends screening for unhealthy alcohol use in primary care settings in adults 18 years or older, including pregnant women, and providing persons engaged in risky or hazardous drinking with brief behavioral counseling interventions to reduce unhealthy alcohol use.	Specific for adults 18 years and older including pregnant women
	99408	Alcohol and/or substance (other than tobacco) abuse structured screening and brief intervention services, 15 to 30 minutes	Specific for adults 18 years and older including pregnant women

	99409	Alcohol and/or substance (other than tobacco) abuse structured screening and brief intervention services, greater than 30 minutes	Specific for adults 18 years and older including pregnant women
	G0396	Alcohol and/or substance (other than tobacco) abuse structured assessment and brief intervention, 15 to 30	Specific for adults 18 years and older including pregnant women
	G0397	Alcohol and/or substance (other than tobacco) abuse structured assessment and intervention, greater than 30 minutes	Specific for adults 18 years and older including pregnant women
	G0442	Annual alcohol misuse screening, 15 minutes	Specific for adults 18 years and older including pregnant women
	G0443	Brief face-to-face behavioral counseling for alcohol misuse, 15 minutes	Specific for adults 18 years and older including pregnant women
	G2011	Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention, 5-14 minutes	Specific for adults 18 years and older including pregnant women
	H0049	Alcohol and/or drug screening	Specific for adults 18 years and older including pregnant women
	H0050	Alcohol and/or drug services, brief intervention, per 15 minutes	Specific for adults 18 years and older including pregnant women
Unhealthy Drug Use Screening: adults age 18 years or older	Part of office visit		Screening refers to just asking questions about drug use, not biological testing
Visual Impairment Screening in Children Younger than age 5	99173	Screening test of visual acuity, quantitative, bilateral	Vision screening at least once in all children ages 3 to 5 year
	99174	Instrument-based ocular screening (e.g., photoscreening, automated-refraction), bilateral; with on-site analysis	Vision screening at least once in all children ages 3 to 5 year
	99177	Instrument-based ocular screening (e.g., photoscreening, automated-refraction), bilateral; with on-site analysis	Vision screening at least once in all children ages 3 to 5 year
Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults; Behavioral Interventions adults	99401	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual (separate procedure) approximately 15 minutes	Specific to adults with a BMI of 30 or higher to refer or offer intensive multicomponent behavioral interventions

	99402	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual (separate procedure) approximately 30 minutes	
	99403	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual (separate procedure) approximately 45 minutes	
	99404	Preventive medicine counseling and/or risk factor reduction intervention provided to an individual (separate procedure) approximately 60 minutes	
Pediatric Immunizations	0091A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose, when administered to individuals 6 through 11 years	0 – 18 years of age
	0092A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; second dose, when administered to individuals 6 through 11 years	
	0093A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; third dose, when administered to individuals 6 through 11 years	
	90378	Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each (90378)	
	90380	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	
	90381	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use	
	90460	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first vaccine/toxoid component administered	

	90461	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine/toxoid component administered (list separately in addition to code for primary procedure)	
	90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid).	
	90472	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)	
	90473	Immunization administration by intranasal or oral route; 1 vaccine (single or combination vaccine/toxoid)	
	90474	Immunization administration by intranasal or oral route; each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)	
	90476	Adenovirus vaccine, type 4, live, for oral use	
	90477	Adenovirus vaccine, type 7, for oral use	
	90620	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB) 32dose schedule, for intramuscular dose	
	90621	Meningococcal recombinant protein vaccine, serogroup B (MenB) 3 dose schedule, for intramuscular use	
	90633	Meningococcal recombinant lipoprotein vaccine serogroup B (MenB), 3 dose schedule for intramuscular	
	90634	Hepatitis A vaccine, pediatric/adolescent dosage - 3 dose schedule for intramuscular use	
	90647	Hemophilus influenza b vaccine (Hib), PRP-OMP conjugate (3 dose schedule), for intramuscular use	
	90648	Hemophilus influenza b vaccine (Hib), PRP-T conjugate(4 dose schedule), for intramuscular use	
	90649	Human Papilloma virus (HPV) vaccine, types 6, 11, 16, 18 (quadrivalent), 3 dose schedule, for intramuscular use	

	90650	Human Papilloma virus (HPV) vaccine, types 16, 18, bivalent, 3 dose schedule for intramuscular use	
	90655	Influenza virus vaccine, split virus, preservative free, when administered to children 6-35 months of age, for intramuscular use	
	90656	Influenza virus vaccine, split virus, preservative free, when administered to individuals 3 years and older, for intramuscular use	
	90657	Influenza virus vaccine, split virus, when administered to children 6-35 months of age, for intramuscular use	
	90658	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use	
	90670	Pneumococcal conjugate vaccine, 13 valent, for intramuscular use	
	90678	Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use	
	90680	Rotavirus vaccine, pentavalent, 3 dose schedule, live, for oral use	
	90681	Rotavirus vaccine, human, attenuated, 2 dose schedule, live, for oral use	
	90682	Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative, and antibiotic free, for intramuscular use	
	90685	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, when administered to children 6-35 months of age, for intramuscular use	
	90686	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, when administered to children 6-35 months of age, for intramuscular use	
	90687	Influenza virus vaccine, quadrivalent (IIV4), split virus, when administered to children 6-35 months of age, for intramuscular use	

	90688	Influenza virus vaccine, quadrivalent (IIV4), split virus, when administered to individuals 3 years of age and older, for intramuscular use	
	90694	Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use	
	90696	Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use	
	90698	Diphtheria, tetanus toxoids, acellular pertussis vaccine,	
		haemophilus influenza Type B, and poliovirus vaccine, inactivated (DTaP - Hib - IPV), for intramuscular use	
	90700	Diphtheria, tetanus toxoids, and acellular pertussis	
		vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use	
	90707	Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use	
	90710	Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use	
	90713	Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use	
	90714	Tetanus and diphtheria toxoids (Td) adsorbed, preservative free, when administered to individual 7 years or older	

	90715	Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older	
	90716	Varicella virus vaccine, live, for subcutaneous use	
	90723	Diphtheria, tetanus toxoids, acellular pertussis vaccine ,Hepatitis B, and poliovirus vaccine, inactivated (DTaP-HepB-IPV), for intramuscular use	
	90732	Pneumococcal polysaccharide vaccine, 23-valent, adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use	
	90733	Meningococcal polysaccharide vaccine [any group(s)], for subcutaneous use	
	90734	Meningococcal conjugate vaccine, serogroups A, C, Y and W-135 (tetraivalent), for intramuscular use	
	90736	Zoster (shingles) vaccine, live, for subcutaneous injection	
	90740	Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (3 dose schedule), for intramuscular use	
	90743	Hepatitis B vaccine, adolescent (2 dose schedule), for intramuscular use	
	90744	Hepatitis B vaccine, pediatric/adolescent dosage (3 dose schedule), for intramuscular use	
	90747	Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (4 dose schedule), for intramuscular use	

	90748	Hepatitis B and Hemophilus influenza b vaccine (HepB-Hib), for intramuscular use	
	90750	Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use	
	90756	Influenza virus vaccine, quadrivalent (cclIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use	
	G0009	Administration of pneumococcal vaccine	
	G0010	Administration of hepatitis B vaccine	
	Q2035	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (AFLURIA)	
	Q2036	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (FLULAVAL)	
	Q2037	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Fluvirin)	
	Q2038	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Fluzone)	
	Q2039	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (not otherwise specified)	
Adult Immunizations	0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose	Adults 19 years of age and older

	0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	
	0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose	
	0004A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose	
	0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose	
	0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose	
	0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19] vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	
	0021A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5×10^{10} viral particles/0.5mL dosage; first dose	

	0022A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage; second dose	
	0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector,	
	0034A	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage, for intramuscular use	
	0041A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, first dose	
	0051A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose	
	0052A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose	
	0053A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose	

	0054A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose	
	0064A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose	
	0071A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	
	0072A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	
	0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation: third dose	
	0074A	immunization administration injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation: booster dose	

	0081A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	
	0082A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	
	0083A	Imm Admin SARSCOV2 3mcg/0.2 mL Tris-Sucrose Third dose	
	0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose	
	0104A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03, emulsion, booster dose	
	0111A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage first dose	
	0112A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage second dose	
	0113A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; third dose	

	0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	
	0134A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, additional dose	
	0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	
	0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose	
	0144A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; additional dose	
	0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	

	0154A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; additional dose	
	0164A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, additional dose	
	0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	
	0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	
	00173A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	
	0174A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; additional dose	
	90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)	

	90472	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each	
		additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)	
	90473	Immunization administration by intranasal or oral route; 1 vaccine (single or combination vaccine/toxoid)	
	90474	Immunization administration by intranasal or oral route; each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)	
	90476	Adenovirus vaccine, type 4, live, for oral use	
	90477	Adenovirus vaccine, type 7. for oral use	
	90581	Anthrax vaccine for subcutaneous or intramuscular use	
	90585	Bacillus Calmette-Guerin vaccine (BCG) for tuberculosis, live, for percutaneous use	
	90586	Bacillus Calmette-Guerin vaccine (BCG) for bladder cancer, live, for intravesical use	
	90611	Smallpox and monkey vaccine, attenuated vaccinia virus, live, non-replicating, preservative, free, 0.5ml dosage, suspension, for subcutaneous use	
	90619	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use	

	90620	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB) 32dose schedule, for intramuscular dose	
	90621	Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB) 3 dose schedule, for intramuscular	
	90622	Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 ml dosage for percutaneous use	
	90630	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use	
	90632	Hepatitis A vaccine, adult dosage, for intramuscular use	
	90634	Hepatitis A vaccine, pediatric/adolescent dosage - 3 dose schedule for intramuscular use	
	90636	Hepatitis A and Hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use	
	90649	Human Papilloma virus (HPV) vaccine, types 6, 11, 16, 18 (quadrivalent), 3 dose schedule, for intramuscular use	
	90650	Human Papilloma virus (HPV) vaccine, types 16, 18, bivalent,3 dose schedule, for intramuscular use	
	90654	Influenza virus vaccine, split virus, preservative-free, for intradermal use	
	90660	Influenza virus vaccine, live, for intranasal use	

	90661	Influenza virus vaccine (cclIV3), derived from cell cultures, subunit, preservative and antibiotic free, for intramuscular use	
	90662	Influenza virus vaccine, split virus, preservative free, enhanced immunogenicity via increased antigen content, for	
	90670	Pneumococcal conjugate vaccine, 13 valent, for intramuscular use	
	90671	Pneumococcal conjugate vaccine, 15 valent, for intramuscular use	
	90672	Influenza virus vaccine, quadrivalent, live, for intranasal use	
	90673	Influenza Virus Vaccine, Trivalent, Derived from Recombinant DNA (RIV3), Hemagglutinin (HA) Protein Only, preservative & antibiotic free, for IM use	
	90674	Influenza virus vaccine, quadrivalent (cclIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	
	90677	Pneumococcal conjugate vaccine, 20 valent, for intramuscular use	
	90689	Influenza virus vaccine, quadrivalent (IIV4), inactivated, adjuvanted, preservative free, 0.25 mL dosage, for intramuscular use	
	90707	Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use	
	90710	Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use	

	90716	Varicella virus vaccine, live, for subcutaneous use	
	90723	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Hepatitis B, and poliovirus vaccine, inactivated (DTaP-HepB- IPV), for intramuscular use	
	90733	Meningococcal polysaccharide vaccine (any group(s)), for subcutaneous use	
	90734	Meningococcal conjugate vaccine, serogroups A, C, Y and W-135 (tetravalent), for intramuscular use	
	90736	Zoster (shingles) vaccine, live, for subcutaneous injection	
	90740	Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (3 dose schedule), for intramuscular use	
	90746	Hepatitis B vaccine, adult dosage, for intramuscular use	
	90747	Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (4 dose schedule), for intramuscular use	
	90748	Hepatitis B and Hemophilus influenza b vaccine (HepB-Hib), for intramuscular use	
	91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	

	91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	
	91302	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage, for intramuscular use	
	91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage, for intramuscular use	
	91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use	
	91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	

	91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	
	91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	
	91308	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	
	91309	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	
	91311	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	

	91312	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	
	91313	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	
	91314	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	
	91315	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	
	91316	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use	

	91317	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	
	G0008	Administration of influenza virus vaccine	
	G0009	Administration of pneumococcal vaccine	
	G0010	Administration of hepatitis B vaccine	
	M0201	Covid-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only covid-19 vaccine administration is performed at the patient's home	
	Q2034	Influenza Virus Vaccine, Split Virus, For Intramuscular Use (AGRIFLU)	
	Q2035	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use	
	Q2036	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use	
	Q2037	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use	

	Q2038	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use	
	Q2039	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use	
Pediatric Preventive Health Care	99381	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender	0 – 18 years of age
	99382	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory /diagnostic procedures, new patient; early childhood (age 1 through 4 years)	
	99383	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; late childhood (age 5 through 11 years)	
	99384	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory /diagnostic procedures, new patient; adolescent (age 12 through 17 years)	
	99391	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering	

	99392	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering	
	99393	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering	
	99394	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering	
	99460	Initial Hospital or birthing center care, per day for evaluation and management of normal newborn infant	
	99461	Initial care, per day, for evaluation and management of normal newborn infant seen in other than hospital or birthing center	
	99463	Initial hospital or birthing center care, per day for evaluation and management of normal newborn infant admitted and discharges on the same date	
	G0438	Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit	
	G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	
	S0612	Annual gynecological examination, established patient	
Adult Preventive Medicine Services	99385	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering laboratory/diagnostic procedures, new patient 18- 39 years old	Adults 19 years of age and older

	99386	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering laboratory/diagnostic procedures, new patient 40 -64 years old	
	99387	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering laboratory/diagnostic procedures, new patient 65 years and older	
	99395	Periodic comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering laboratory/diagnostic procedures, new patient 18- 39 years old	
	99396	Periodic comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering laboratory/diagnostic procedures, new patient 40 -64 years old	
	99397	Periodic comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering laboratory/diagnostic procedures, new patient 65 years and older	
	G0438	Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit	
	G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	

	S0610	Annual gynecological examination, new patient	
	S0612	Annual gynecological examination, established patient	